The Treatment of Acute Myelogenous Leukemia in Children and Adults: VAPA Update
Major progress in the treatment of acute myelogenous leukemia (AML) has occurred during the past decade. Advances in chemotherapy and supportive care have been associated with an increase in the complete remission rate of patients under the age of 60 with AML from 35%–55% [5, 7] to approximately 75% [2, 9, 16]. More importantly, the median duration of complete remission and the percentage of patients in long-term continuous complete remission has steadily improved. This has resulted from postinduction combination chemotherapy [10, 13, 18, 20] or chemoradiotherapy and transplantation of marrow from histocompatible siblings [4, 15, 21]. In 1976 the VAPA protocol was initiated to specifically improve the duration of complete remission for children and adults (< 50 years) with AML. In 1980 we reported encouraging results obtained with this approach [12, 22], and this report is an update of the study.
KeywordsComplete Remission Acute Myelogenous Leukemia Cytosine Arabinoside Monocytic Leukemia Central Nervous System Relapse
Unable to display preview. Download preview PDF.
- 2.Baehner RL, Bernstein ID, Sather H, Higgins G, McCreadie S, Chard RL, Hammond D (1979) Improved remission induction rate with D-ZAPO but unimproved remission duration with addition of immunotherapy to chemotherapy in previously untreated children with ANLL. Med Pediatr Oncol 7: 127PubMedCrossRefGoogle Scholar
- 6.Chard RL, Finkelstein JZ, Sonlez MJ, Nesbit M, McCreadie S, Weiner J, Sather H, Hammond D (1978) Increased survival in childhood acute non-lymphocytic leukemia after treatment with prednisone, cytosine arabinoside, 6-thioguanine, cyclophosphamide, and oncovin (PATCO) combination chemotherapy. Med Pediatr Oncol 4:263–273PubMedCrossRefGoogle Scholar
- 12.Mayer RJ, Weinstein HJ, Rosenthal DS, Coral, FS, Nathan DG, Frei E III (1981) VAPA 10: a treatment program for acute myelocytic leukemia. In: Neth R, Gallo RC, Graf T, Mannweiler K, Winkler K (eds) Modern Trends in Human Leukemia IV. Springer, Berlin Heidelberg New York (Haematology and Blood transfusion, vol 26)Google Scholar
- 17.Preisler H, Browman G, Henderson ES (1980) Treatment of acute myelocytic leukemia: Effects of early intensive consolidation. Proc Am Assoc Clin Oncol Abstract C-493Google Scholar
- 19.Skipper HE (1978) Reasons for success and failure in treatment of murine leukemias with drugs now employed in treating human leukemias. In: Cancer chemotherapy, vol I. University Microfilms International. Southern Research InstituteGoogle Scholar
- 24.Wiernik PH, Schimpff SC, Schiffer CA, Lichtenfeld JL, Aisner J et al. (1976) Randomized clinical comparison of daunorubicin alone with a combination of daunorubicin, cytosine arabinoside, 6-thioguanine, and pyrimethamine for the treatment of acute non-lymphocytic leukemia. Cancer Treat Rep 60:41–53PubMedGoogle Scholar